Ekf Diagnostics Share Discussion Threads

[mysteronz] 19/5/2021 07:22

We are already in discussions with our private sector partner, with whom we have a recently signed, multi-million dollar global supply contract, regarding the expansion of our support beyond their world-wide COVID-19 testing programme for their staff, to supporting a much broader commercial testing capacity to cover other areas of infectious disease, chronic disease and general health and wellness.

Sounds great! Anything with ‘that’ company isnt going to be small beer!

[hastings] 19/5/2021 07:13

Excellent news, couldn't ask for more, the runway is extensive!

[faz] 19/5/2021 07:10

Shanklin, this has not been an ordinary year. My point was the share price movement indicated a statement was coming and the way EKF has flexed and grown in the last year would make no statement an odd decision. Also being so particualrly invited to the meeting suggested to me anyway they had somehting to tell. And wow they have!

[rivaldo] 19/5/2021 07:08

Lovely stuff in the AGM statement today:

"the Board is now confident that trading for the full year will be comfortably ahead of already upgraded management expectations"

Even better are the various plans going forward, which look transformative.

It's also great (from EKF's perspective anyway) to hear that its COVID-19 business will "continue for many years to come".

[shanklin] 19/5/2021 07:06

Very happy to be wrong about the provision of a TS today :-)))))))))))))

[tongosti] 18/5/2021 18:04

Could be wishful thinking imo

[shanklin] 18/5/2021 16:12

What AGM statement?

There hasn't been an update on trading on AGM day in the last two years. Will this year be different for some reason?

[faz] 18/5/2021 14:29

Amazing how it happens every time just before information release dates - up 5% today. I bought more yesterday morning and look forward to the AGM statement; I've got my seat booked.

[tongosti] 18/5/2021 12:56

Surely you mean food for ramping old chap

[wan] 18/5/2021 11:34

And I also find myself asking (myself!).....what is it that is making it confidentially restricted as to who EKF's private sector partner is? Food for thought!

[mg1982] 18/5/2021 11:21

quick Tong,

declare that you're long EKF from 60p (60.2p after cost we know how precise you are...) today cos Mr Market gave you free shares for the ride.

Wouldn't want anyone dare saying you're a blagger

Quick mate, it's about to explode

[wan] 18/5/2021 11:20

Importantly, it should also be noted how well telehealth and digital health offerings dovetails with near patient testing/at-home testing, and self-collection tests etc.

[wan] 18/5/2021 10:30

Back to EKF's core diagnostic business -

Some investors may have noted that PerkinElmer is to buy Immunodiagnostic Systems (IDH) for a significant premium to its volume weighted average share price. Making it PerkinElmer's 3rd acquisition this year, and further demonstrates the interest and likelihood of further M&A in our sector.

I am expecting that interest to also extend to and include near patient testing, given that the pandemic has also opened many companies eyes to the possibility of using point of care testing (POCT), as well as at-home testing and self-collection for other disease states, for the valuable role that can play in healthcare in general, even where POCT wasn't a part of their existing portfolio's.

During a recent 360DX roundtable on the post-vaccine testing landscape, Nathan Ledeboer, medical director of clinical microbiology and molecular diagnostics at Froedtert Hospital and the Medical College of Wisconsin, said that he believed that the shift to at-home testing and self-collection "precipitated as a result of COVID is going to fundamentally reshape the diagnostics industry and healthcare in general," and added that he thought this reshaping would prove to be one of the major impacts of the pandemic -
shorturl.at/msBGJ

With a senior VP at Laboratory Corporation of America, also recently saying that COVID-19 was driving a "paradigm shift" toward home testing.

So, with exposure to laboratory diagnostics market, rapid testing and POC testing markets, and a firm footing established in self-collection (and potentially at-home testing), not to mention having the expertise and experience in navigating the tough regulatory hurdles to obtain the necessary approvals, EKF is very well placed indeed to flourish today and 'beyond' the pandemic!

[cambridgedon] 18/5/2021 10:21

All good stuff!
No price announced yet. If it follows the RNLX model it will be over-subscribed with a healthy premium.
CD

[tongosti] 18/5/2021 10:10

Market at 66 - excitement in the air?

[riddlerone] 18/5/2021 08:55

Morning Rivaldo,Thats exactly what I have just done and as you said blown someone's mind at 8.30 in the morning.Speed is of the essence with this one so if anyone gets any more info would be great to share GLA

[wan] 18/5/2021 08:48

Yes indeed, Trellus is yet another example and result of the managements foresight and efforts in providing returns to shareholders via the dividend in specie and IPO route, which the management see as providing shareholders with a far greater reward than just paying a cash dividend.

So, it's worth bearing in mind that EKF are aiming to do one investment and one floatation per year, and are thus hoping to do another spin off next year (technology investment yet to be revealed/decided, but one would obviously expect an announcement on such a decision/investment to be well in advance of a spin-off for next year).

With new technologies and spin-offs firmly in mind, and food for thought, I do wonder what might be in store for Kantaro Biosciences -

We ensure that high-quality diagnostics tests for critical health challenges are accessible.

Kantaro is a joint venture of the Mount Sinai Health System and RenalytixAI (NASDAQ:RNLX).

We specialize in the rapid scale up of groundbreaking diagnostic innovations and the creation of partnerships to bring these crucial technologies to the market. Together with our partners, we provide academically rigorous, validated and results-driven diagnostics with the goal to advance the well-being of people, communities and society.

[rivaldo] 18/5/2021 08:44

It appears that as a Qualifying Shareholder of Trellus via my dividend in specie, I can apply for additional IPO shares. However, as the shares are presumably held at this stage beneficially for me and likely almost all PIs by our stockbrokers, I now have to contact my stockbroker to obtain application instructions for me and then submit that application. Which probably means (knowing most brokers) that they'll be completely unaware of any of this and will have to look into it and scramble to manage the process in time.

Can someone confirm that I've understood this correctly please?!

[masurenguy] 18/5/2021 07:24

Intention to Float on AIM

Proposed placing, subscription and restricted offer

LONDON, UK. AND NEW YORK, U.S. (18 May 2021). Trellus Health plc (AIM: TRLS), which is commercialising a scientifically validated, resilience-based, connected health solution for chronic condition management, confirms its intention to seek admission of its issued share capital, as enlarged by a proposed placing, subscription and a restricted offer (together, the "Fundraising"), to trading on AIM ("Admission"). Trellus Health is pleased to announce that it has received strong indications of demand for the placing of new ordinary shares in the capital of the Company ("Ordinary Shares" or "Trellus Shares") and] also confirms the launch of a restricted offer, to be made available for a limited period only to qualifying Trellus Health shareholders. Further information on the Restricted Offer is contained below. This release is being linked to the EKF ticker for information purposes only.

[mirandaj] 17/5/2021 22:14

There are a number of these reports around these days but this one caught my eye for obvious reasons

"POC Glycated Hemoglobin Analyzer Market to Witness Huge Growth by 2026 | Alere, Siemens, Roche, Trinity Biotech, GREEN CROSS MEDIS, EKF Diagnostics"

[faz] 17/5/2021 10:10

Interesting to see on the Open Orph thread that Salim Hamir, Board sec at EKF, verici and Renx, has become a director of Poolbeg Pharma, the likely vehicle for one of Open Orph's spin out businesses. There was much a while back on the Orph BB talk of how EKF had enriched shareholders through spinouts; seems talk was also being had in its Boardroom.

[wan] 17/5/2021 09:36

To confirm why the above is worthy of note -

It was previously announced by Myhealthchecked that the MyHealthChecked™ COVID-19 testing service will use the PrimeStore® MTM sample collection device supplied by EKF Diagnostic Holdings plc.

The new Day 2 and Day 8 COVID-19 Travel Test Package also contains two PrimeStore MTM tubes (if you look closely enough) -

So, it is likely that all the various test kits contain PrimeStore MTM, and it's likely that EKF assembles the various test kit packages too -


Excerpt from the Chief Executive’s Review (Annual Report) -

In what has been a year like no other I have been astounded at how my colleagues
at EKF have been able to adapt to the pandemic, support a solid core business
performance and introduce a new manufacturing capability from zero to a business that is now manufacturing hundreds of thousands of COVID-19 sample collection kits per annum. All the credit for this past 12 months has to go to the incredible employees at EKF in Wales, Germany and the US.

[wan] 17/5/2021 07:11

Worthy of note -

MyHealthChecked PLC Additional Boots agreement for D2/D8 testing
17/05/2021 7:00am
UK Regulatory (RNS & others)

Additional Boots agreement for Day 2 & Day 8 testing

Extends supply of COVID-19 testing services for international arrivals to the UK

MyHealthChecked Plc (AIM: MHC), the consumer home-testing healthcare company, announces it has on 16 May signed a second contract with Boots UK Limited ("Boots"), the health and beauty retailer and pharmacy group, to supply the MyHealthChecked(TM) COVID-19 at-home nasal swab kit, laboratory testing service and logistics for day two and day eight ("D2/D8") coronavirus testing for international arrivals.

The contract with Boots for the D2/D8 testing service will run parallel, and be complementary, to the Company's pre-existing agreement, announced on 6 April 2021 . MyHealthChecked is currently the only at-home PCR testing kit provider within Boots for General Testing and Fit-to-Fly services, launched on 7 April, and now expands the offering within Boots to include D2/D8 tests that will be available to purchase online, via www.boots.com across the UK, from May 17.

The MyHealthChecked(TM) COVID-19 testing kit allows customers to take a nasal swab themselves at home and send samples safely and securely via the Royal Mail Tracked 24 service to be tested using established laboratory-based PCR detection methods. D2/D8 testing is undertaken at the Manchester-based laboratories of MyHealthChecked and Yourgene Health plc (AIM: YGEN), with any sequencing required for positive day 2 samples that meet the DHSC sequencing criteria, undertaken at Yourgene Health plc. PCR results are provided to customers within 24-48 hours, via a secure online portal.

The Agreement is on a non-exclusive basis and has an initial term of 12 months from 17 May 2021, with a one-month notice period for termination thereafter.

The contract is expected to have a significant impact on the future performance of the MHC business and whilst volumes are unquantified at this stage, the Board believes it is likely to result in substantial revenue growth in the current financial year ending 31 December 2021.

MyHealthChecked(TM) also offers the testing kits online via www.myhealthchecked.com .

Penny McCormick, Chief Executive Officer of MyHealthChecked Plc, said: "This is another milestone for MyHealthChecked as currently Boots' only at-home testing kit provider for COVID-19, and we are delighted to build on our pre-existing agreement as the nation begins to open up and we anticipate the possibility of travel with the introduction of the traffic light system. The D2/D8 contract is a testament to the service that MyHealthChecked provides as we pride ourselves on the quality and accuracy of our tests, as well as our operations and customer service.

"We look forward to continuing our partnership with Boots and while it is still in its infancy, we hope to update the market imminently as we deliver on this contract."

Full release -

[mirandaj] 14/5/2021 16:28

From December - the facts:



On 11 December 2020 the board of EKF (the "Board") convened and declared a dividend in specie of shares in Trellus to trustees, to be held on trust for the Company's shareholders (the "Dividend"). EKF's investment in Trellus comprises 27,999,999 A Shares of £0.0001 each and 1 golden share of £0.0001 (the "Golden Share"). The Golden Share is the voting share in the capital of Trellus and will be retained by the Company. The Company's shareholders on the register as at close of business on 17 December 2020 ("Relevant EKF Shareholders") will receive one A Share (each a "Dividend Share") for every 16.25 ordinary share held in the Company.

Relevant EKF Shareholders will become the beneficial owners of their respective Dividend Shares upon completion of the transfer of the Dividend Shares to Broadway Nominees Limited ("Broadway"), at which time an 'omnibus' share certificate in respect of the Dividend Shares will be issued and held by Broadway, to be held on trust by it on behalf of the Relevant EKF Shareholders for a period of:

· 365 days following admission to trading on AIM (or another recognised stock exchange) of the issued share capital of Trellus; or

· if the issued share capital of Trellus is not admitted to trading on AIM (or another recognised stock exchange) within two years of the date that the Dividend is settled, two years from the date that the Dividend is settled (the "Lock-up Period").

During the Lock-up Period, Relevant EKF Shareholders will not be permitted to transfer the legal or beneficial ownership of their Dividend Shares.

The A Shares and the Golden Share will, on the earlier of the admission to trading of Trellus on AIM (or another recognised stock exchange) and two years from the date that the Dividend is settled, automatically convert into ordinary shares in Trellus ("Ordinary Shares") on the basis of one Ordinary Share for each A Share or Golden Share held. If Trellus is admitted to trading on AIM (or another recognised stock exchange), the Lock-up Period will continue to apply to the converted Ordinary Shares. All converted Ordinary Shares will rank equally in all respects with all other Ordinary Shares including in respect of voting and dividend rights.

The legal title to the Dividend Shares will be held by Broadway as trustee, during the Lock-Up Period. If the A Shares are converted into Ordinary Shares during the Lock-up Period, Broadway will request that Trellus' registrar seeks the voting instructions of the Relevant EKF Shareholders in relation to any shareholder resolution of Trellus and will vote those Dividend Shares in accordance with such instructions as it receives . At the end of the Lock-up Period, Broadway will execute stock transfer forms to transfer the Dividend Shares to the Relevant EKF Shareholders based on a schedule provided by the Company's registrar.

Relevant EKF Shareholders will receive a letter informing them of their beneficial holdings of Dividend Shares shortly after the transfer of the Dividend Shares to Broadway.

Following the Lock-up Period, Relevant EKF Shareholders will receive individual certificates in respect of their Dividend Shares.

The anticipated timetable for the Dividend is:



EKF ordinary shares marked as ex rights

Start of trading on 16 December 2020

Record date for the distribution of the Dividend

Close of business on 17 December 2020

Transfer of shares in Trellus to Broadway as trustee

18 December 2020

The undertaking in relation to Broadway acting as legal holder of the Dividend Shares can be accessed via the investor section of the Company's website.